Capecitabine Tablets Wholesale price comparison
$7.00
Capecitabine is an oral prodrug of 5?fluorouracil used in chemotherapy. Supplied as 0.5?g tablets (12 per box) by Shanghai Shenyang Yiying Pharmaceutical Co., Ltd., approved in China under NMPA No. H20233900 (Product Code: 86981288000046; Barcode: 6920257000162). For laboratory research only ?Please consult the staff for other purposes?
描述
Capecitabine Tablets Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Capecitabine Tablets (Shanghai Synyi) |
| Strength | 0.5?g per tablet |
| Quantity | 12 tablets per box |
| Formulation | Oral tablet |
| Approval No. | China NMPA H20233900 |
| Product Code | 86981288000046 |
| Barcode | 6920257000162 |
| Manufacturer | Shanghai Shenyang Yiying Pharmaceutical Co., Ltd. |
| Intended Use | Laboratory research use only — Not for human or veterinary use |
Mechanism of Action
Capecitabine is a tumor-selective prodrug of 5?fluorouracil (5-FU). Once ingested, it is converted to 5-FU in tumors by thymidine phosphorylase, disrupting DNA synthesis via thymidylate synthase inhibition and blocking RNA function .
Research & Reference Data
-
High oral bioavailability (~100%), with C??? at ~1.5–2?h; primarily excreted renally (~95%) .
-
Widely used as a standalone or combination therapy in colorectal, breast, gastric, and pancreatic cancer en.wikipedia.org+3pubmed.ncbi.nlm.nih.gov+3mayoclinic.org+3.
-
Common toxicities include diarrhea, hand-foot syndrome, mucositis, myelosuppression, elevated bilirubin; watch for DPD deficiency?linked severe toxicity
Research Applications
-
In vitro/in vivo tumor models (e.g., colorectal, breast cancer)
-
Drug metabolism and pharmacokinetic studies
-
Toxicity profiling and DPD-deficiency modeling
-
Combination therapy exploration with chemotherapeutics or targeted agents
?? Research?Use Disclaimer
This product is provided strictly for laboratory research and development use only. Not intended for human, veterinary, clinical, diagnostic, or therapeutic applications.
其他信息
| 重量 | 1.1 公斤 |
|---|---|
| 尺寸 | 18 × 16 × 16 厘米 |
相关产品
-
Ivodazumab Injection (lvonescimab) – 10?ml per Vial [For Laboratory Research Only]
Ivodazumab (Yidafang®) is a monoclonal antibody developed by Kangfang Pharmaceutical Co., Ltd., approved by China's NMPA (Approval No. S20240020; Drug Code: 86985204000011). Each vial contains 10?ml of the injectable formulation. Strictly for laboratory research use only—not for clinical or human use.
$1.00 -
Mechlorethamine Hydrochloride Injection (HaiPu®) – 1?mL:5?mg Vial Price Comparison
Mechlorethamine hydrochloride (HaiPu®) is a potent DNA-alkylating agent from the nitrogen mustard class, supplied as a 1?mL vial containing 5?mg. Manufactured by Shanghai Xudong Haipu Pharmaceutical Co., Ltd., with NMPA approval H31020897 and product code 86900808000625. Strictly for laboratory research use.?Please consult the staff for other purposes? $1.00 -
Limertinib Tablets 80?mg ×?20 – by Osscon Pharma | Research Use Only (3rd?Gen EGFR?TKI)
Limertinib (OuyiXin®) is a third-generation EGFR tyrosine kinase inhibitor (EGFR?TKI) at 80?mg per tablet, 20 tablets per box, from Jiangsu Osscon Pharmaceutical. Approved by China’s NMPA under H20250004, it targets EGFR T790M?mutated non?small cell lung cancer, including patients with brain metastases.
?? For research use only – Not for human consumption or therapeutic use. $1.00 -
Lparomlimab & Tuvonralimab Injection (Qibeian) – 50?mg/2?mL Vial Price comparison
Lparomlimab & Tuvonralimab Injection Qibeian is a bi-functional monoclonal antibody combination (PD?1/CTLA?4) developed by Qilu Pharmaceutical (QL1706), supplied as 50?mg in 2?mL vials. Approved by China’s NMPA (conditional marketing authorization No. S20240044; drug code 86904021005238). Intended exclusively for lab and investigative research applications, not for clinical or human use. $1.00
评价
目前还没有评价